BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension A Meta-analysis

被引:11
作者
McCarthy, Breanne E. [1 ,2 ]
McClelland, Robyn L. [4 ]
Appleby, Dina H. [3 ]
Moutchia, Jude S. [3 ]
Minhas, Jasleen K. [1 ,2 ]
Min, Jeff [1 ,2 ]
Mazurek, Jeremy A. [1 ,2 ]
Smith, K. Akaya [1 ,2 ]
Fritz, Jason S. [1 ,2 ]
Pugliese, Steven C. [1 ,2 ]
Urbanowicz, Ryan J. [4 ]
Holmes, John H. [4 ]
Palevsky, Harold I. [1 ,2 ]
Kawut, Steven M. [1 ,2 ,4 ]
Al-Naamani, Nadine [1 ,2 ]
机构
[1] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Departmentof Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA
[3] Univ Penn, Perelman Sch Med, Philadelphia, PA USA
[4] Univ Washington Sch Publ Hlth, Dept Biostat, Seattle, WA USA
基金
美国国家卫生研究院;
关键词
BMI; meta-analysis; obesity; pulmonary arterial hypertension; RECEPTOR ANTAGONIST; ORAL TREPROSTINIL; DOUBLE-BLIND; THERAPY; SURVIVAL; EFFICACY; REGISTRY; OBESITY; EPIDEMIOLOGY; AMBRISENTAN;
D O I
10.1016/j.chest.2022.02.041
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Obesity is increasingly prevalent in pulmonary arterial hypertension (PAH) but is associated with improved survival, creating an "obesity paradox " in PAH. It is unknown if the improved outcomes could be attributable to obese patients deriving a greater benefit from PAH therapies. RESEARCH QUESTION: Does BMI modify treatment effectiveness in PAH? STUDY DESIGN AND METHODS: Using individual participant data, a meta-analysis was conducted of phase III, randomized, placebo-controlled trials of treatments for PAH submitted for approval to the U.S. Food and Drug Administration from 2000 to 2015. Primary outcomes were change in 6-min walk distance (6MWD) and World Health Organization (WHO) functional class. RESULTS: A total of 5,440 participants from 17 trials were included. Patients with overweight and obesity had lower baseline 6MWD and were more likely to be WHO functional class III or IV. Treatment was associated with a 27.01-m increase in 6MWD (95% CI, 21.58-32.45; P < .001) and lower odds of worse WHO functional class (OR, 0.58; 95% CI, 0.48-0.70; P < .001). For every 1 kg/m(2) increase in BMI, 6MWD was reduced by 0.66 m (P = .07); there was no significant effect modification of treatment response in 6MWD according to BMI (P for interaction = .34). Higher BMI was not associated with odds of WHO functional class at end of follow-up; however, higher BMI attenuated the treatment response such that every 1 kg/m(2) increase in BMI increased odds of worse WHO functional class by 3% (OR, 1.03; P for interaction = .06). INTERPRETATION: Patients with overweight and obesity had lower baseline 6MWD and worse WHO functional class than patients with normal weight with PAH. Higher BMI did not modify the treatment response for change in 6MWD, but it attenuated the treatment response for WHO functional class. PAH trials should include participants representative of all weight groups to allow for assessment of treatment heterogeneity and mechanisms.
引用
收藏
页码:436 / 447
页数:12
相关论文
共 55 条
[1]   Relation Between Obesity and Survival in Patients Hospitalized for Pulmonary Arterial Hypertension (from a Nationwide Inpatient Sample Database 2003 to 2011) [J].
Agarwal, Manyoo ;
Agrawal, Sahil ;
Garg, Lohit ;
Lavie, Carl J. .
AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (03) :489-493
[2]   Pulmonary Arterial Hypertension Baseline Characteristics From the REVEAL Registry [J].
Badesch, David B. ;
Raskob, Gary E. ;
Elliott, C. Greg ;
Krichman, Abby M. ;
Farber, Harrison W. ;
Frost, Adaani E. ;
Barst, Robyn. J. ;
Benza, Raymond L. ;
Liou, Theodore G. ;
Turner, Michelle ;
Giles, Scott ;
Feldkircher, Kathy ;
Miller, Dave P. ;
McGoon, Michael D. .
CHEST, 2010, 137 (02) :376-387
[3]   United States Pulmonary Hypertension Scientific Registry Baseline Characteristics [J].
Badlam, Jessica B. ;
Badesch, David B. ;
Austin, Eric D. ;
Benza, Raymond L. ;
Chung, Wendy K. ;
Farber, Harrison W. ;
Feldkircher, Kathy ;
Frost, Adaani E. ;
Poms, Abby D. ;
Lutz, Katie A. ;
Pauciulo, Michael W. ;
Yu, Chang ;
Nichols, William C. ;
Elliott, C. Gregory .
CHEST, 2021, 159 (01) :311-327
[4]   Sitaxsentan therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
Langleben, D ;
Frost, A ;
Horn, EM ;
Oudiz, R ;
Shapiro, S ;
McLaughlin, V ;
Hill, N ;
Tapson, VF ;
Robbins, IM ;
Zwicke, D ;
Duncan, B ;
Dixon, RAF ;
Frumkin, LR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447
[5]   Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan [J].
Barst, Robyn J. ;
Langleben, David ;
Badesch, David ;
Frost, Adaani ;
Lawrence, E. Clinton ;
Shapiro, Shelley ;
Naeije, Robert ;
Galie, Nazzareno .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) :2049-2056
[6]   Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials [J].
Benza, Raymond L. ;
Gomberg-Maitland, Mardi ;
Naeije, Robert ;
Arneson, Carl P. ;
Lang, Irene M. .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (09) :982-989
[7]   Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ [J].
Burke, Danielle L. ;
Ensor, Joie ;
Riley, Richard D. .
STATISTICS IN MEDICINE, 2017, 36 (05) :855-875
[8]   Endothelin receptor antagonists in pulmonary arterial hypertension [J].
Dupuis, J. ;
Hoeper, M. M. .
EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (02) :407-415
[9]   Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells [J].
Favre, Shirley ;
Gambini, Elisa ;
Nigro, Patrizia ;
Scopece, Alessandro ;
Bianciardi, Paola ;
Caretti, Anna ;
Pompilio, Giulio ;
Corno, Antonio F. ;
Vassalli, Giuseppe ;
von Segesser, Ludwig K. ;
Samaja, Michele ;
Milano, Giuseppina .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2017, 21 (05) :871-880
[10]   Obesity Is Associated With Pulmonary Hypertension and Modifies Outcomes [J].
Frank, Rachel C. ;
Min, Jeff ;
Abdelghany, Mazin ;
Paniagua, Samantha ;
Bhattacharya, Romit ;
Bhambhani, Vijeta ;
Pomerantsev, Eugene ;
Ho, Jennifer E. .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (05)